What is ReCode Therapeutics?
ReCode Therapeutics is a clinical-stage genetic medicines company dedicated to the development of transformative therapies for both rare and common diseases. At the core of its operations is the proprietary SORT (Selective Organ Targeting) lipid nanoparticle platform, which enables the precise delivery of genetic payloads to specific tissues. This technological edge allows the company to overcome traditional barriers in gene therapy, offering a more effective and targeted approach to treating underlying disease mechanisms. By focusing on precision medicine, ReCode is positioning itself as a critical player in the next generation of biopharmaceutical innovation.
How much funding has ReCode Therapeutics raised?
ReCode Therapeutics has raised a total of $415.4M across 6 funding rounds:
Angel/Seed
$2M
Series A
$80M
Private Equity
$15M
Series B
$260M
Other Financing Round
$29M
Debt
$29.4M
Angel/Seed (2019): $2M, investors not publicly disclosed
Series A (2020): $80M led by Colt Ventures, MPM BioImpact, Osage University Partners, OrbiMed, Vida Ventures, and Hunt Technology Ventures
Private Equity (2023): $15M supported by Cystic Fibrosis Foundation
Series B (2023): $260M featuring Superstring Capital, MPM BioImpact, Osage University Partners, OrbiMed, Pfizer, Vida Ventures, Sanofi Ventures, Solasta Ventures, BLV, Colt Ventures, Hunt Technology Ventures, EcoR1 Capital, NS Investment, and Tekla Healthcare Opportunities
Other Financing Round (2025): $29M, investors not publicly disclosed
Debt (2025): $29.4M, investors not publicly disclosed
Key Investors in ReCode Therapeutics
MPM BioImpact
MPM BioImpact manages early-stage venture funds, private/public impact funds and a public equities fund. We convert science into therapeutics to reach the patients that need them most.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains.
Osage University Partners
Osage University Partners is a venture capital firm that exclusively invests in innovative startups emerging from leading universities and research institutions worldwide.
What's next for ReCode Therapeutics?
With the recent $29.4M in capital, ReCode Therapeutics is well-positioned to accelerate its clinical pipeline and expand the reach of its SORT platform. The strategic focus will likely shift toward advancing lead candidates through human trials while simultaneously exploring new therapeutic applications for its delivery technology. As the company matures, it will continue to leverage its strong investor syndicate to navigate the complexities of regulatory approval and commercial scaling, aiming to deliver life-changing outcomes for patients globally.
See full ReCode Therapeutics company page
